These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 2574194

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study.
    Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, Joe SH.
    Psychiatry Clin Neurosci; 2010 Feb; 64(1):19-27. PubMed ID: 19968833
    [Abstract] [Full Text] [Related]

  • 6. Buspirone in the treatment of tardive dyskinesia.
    Moss LE, Neppe VM, Drevets WC.
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [Abstract] [Full Text] [Related]

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 8. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T, Furuya M, Yasuda H, Hayashida M, Nishida A, Inagaki T, Horiguchi J.
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr 01; 32(3):761-4. PubMed ID: 18201810
    [Abstract] [Full Text] [Related]

  • 9. Bromocriptine in tardive dyskinesia.
    Häggström JE, Andersson U, Gunne LM.
    Pharmacopsychiatria; 1982 Sep 01; 15(5):161-3. PubMed ID: 6129649
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Vitamin B6 add-on therapy in treatment of schizophrenic patients with psychotic symptoms and movement disorders].
    Miodownik C, Cohen H, Kotler M, Lerner V.
    Harefuah; 2003 Sep 01; 142(8-9):592-6, 647. PubMed ID: 14518160
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.
    Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA.
    J Affect Disord; 2004 Dec 01; 83(2-3):263-75. PubMed ID: 15555724
    [Abstract] [Full Text] [Related]

  • 16. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW, Gueorguieva RV, Baker CB, Makuch RW.
    Arch Gen Psychiatry; 2005 Sep 01; 62(9):961-70. PubMed ID: 16143728
    [Abstract] [Full Text] [Related]

  • 17. Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis.
    Singh H, Hunt JI, Vitiello B, Simpson GM.
    J Clin Psychiatry; 1990 Aug 01; 51(8):319-21. PubMed ID: 1974249
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 01; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.